Effect of Tebipenem on Normal Human Intestinal Microbiota
Phase 1 Study to Evaluate the Effect of Oral Administration of Tebipenem Pivoxil Hydrobromide on Normal Human Intestinal Microbiota in Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Stockholm
-
Huddinge, Stockholm, Sweden
- Karolinska University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult males and/or females, ≥18 years of age at the time of screening;
- Medically healthy without clinically significant abnormal values for hematology, clinical chemistry, urinalysis, physical examination, vital signs, or ECG as determined by the investigator during the screening period. Discussion is encouraged between the Investigator and the Sponsor Medical Monitor regarding the clinical relevance of any abnormal laboratory value during the pre-dose period;
- Willing and able to provide written informed consent;
- Willing and able to comply with all study assessments and adhere to the protocol schedule, including all scheduled post-therapy visits;
- Have suitable venous access for blood sampling;
- Women of childbearing potential (WOCBP*) must use a highly effective form of birth control (confirmed by the Investigator). Rhythm methods will not be considered as highly effective methods of birth control. WOCBP must agree to use a highly effective method of birth control, as defined above, from signing the Informed Consent Form (ICF), throughout the study duration and until 30 days after the last dose of study drug;
- Non-vasectomized male volunteers must use an adequate method of contraception (condom or condom with spermicide, depending on local regulations) from the time of signing the ICF, throughout the study duration and until 30 days after the last dose of study drug. Men with a partner who is (are) not of childbearing potential are exempt from these requirements;
- Male volunteers must not donate sperm for time of signing the ICF until at least 30 days after the last dose of the study drug
Exclusion Criteria:
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or surgery within the past 3 months determined by the Investigator to be clinically relevant;
- History or presence of known or suspected gastrointestinal disorder, including but not limited to Clostridioides difficile infection, inflammatory bowel disease, recent history of food poisoning or other stomach/intestinal disorders including gastroenteritis (within 6 months);
- History of systemic antibiotic treatment during the last three months prior to randomization;
- Use of any systemic prescription medication or any systemic over-the-counter medication, including herbal products and vitamins or probiotics within 7 days prior to randomization; except for hormonal contraceptives and the intermittent use of paracetamol, ibuprofen, and antihistamines;
- Alanine transaminase (ALT) or aspartate transaminase (AST) >5 × upper limit of normal and CrCl of ≤50 mL/min, as estimated by the Lund-Malmö revised formula;
- History of seizure disorders, except for febrile seizures in childhood;
- History of substance or alcohol abuse and positive urine drug testing at screening. History of substance or alcohol abuse and negative urine drug testing at screening can be enrolled in study based on the Investigator's discretion;
- Positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV);
- Documented or suspected hypersensitivity reaction or anaphylaxis to β-lactam antibiotics (e.g., cephalosporins, penicillins, carbapenems), product excipients (Mannitol, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and film coating systems [Opadry]) or any contraindication to the use of amoxicillin- clavulanate;
- Participation in another investigational clinical study within 3 months prior to Day 1;
- Current or anticipated need for systemic antibiotics, probiotics, or laxatives during the study;
- Any other condition or prior therapy, which, in the opinion of the Investigator, would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likely to be non-compliant with any study requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TBPM-PI-HBr
Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) for 10 days.
|
TBPM-PI-HBr (2 x 300mg tablets) PO q8h [±1 hour] for 10 days
Other Names:
|
|
Active Comparator: amoxicillin-clavulanate
Healthy subjects meeting eligibility criteria will be sequentially randomized to receive either 500/125mg amoxicillin-clavulanate PO q8h (±1 hour) or 600mg TBPM-PI-HBr every 8 hours (PO q8h [±1 hour]) or for 10 days.
|
amoxicillin-clavulanate (1 × 500mg/125mg tablet) PO q8h [±1 hour] for 10 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in the number of microorganisms in the intestinal flora of healthy subjects during and after 10 days of oral administration of TBPM-PI-HBr or amoxicillin-clavulanate
Time Frame: Change from baseline (Day-1), at Days 2, 4, 7, 10, 14, 21, 90, and 180
|
Changes in the number of microorganisms identified in feces
|
Change from baseline (Day-1), at Days 2, 4, 7, 10, 14, 21, 90, and 180
|
|
Changes in the types of microorganisms in the intestinal flora of healthy subjects during and after 10 days of oral administration of TBPM-PI-HBr or amoxicillin-clavulanate
Time Frame: Change from baseline (Day-1), at Days 2, 4, 7, 10, 14, 21, 90, and 180
|
Changes in the types of microorganisms identified in feces
|
Change from baseline (Day-1), at Days 2, 4, 7, 10, 14, 21, 90, and 180
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To explore the potential for development of resistance by measuring the number of new colonizing bacterial isolates
Time Frame: Change from baseline (Day-1), at Days 2, 4, 7, 10, 14, 21, 90, and 180
|
Emergence of resistant strains with increasing minimum inhibitory concentration values during treatment and post-treatment with tebipenem and amoxicillin-clavulanate will be determined from fecal samples.
|
Change from baseline (Day-1), at Days 2, 4, 7, 10, 14, 21, 90, and 180
|
|
To assess the plasma concentrations of tebipenem over 10 days of oral administration of TBPM-PI-HBr.
Time Frame: Day 1 through Day 14
|
PK concentration of tebipenem will be measured in plasma.
Concentrations of tebipenem will be plotted for each participant.
|
Day 1 through Day 14
|
|
To assess the fecal concentrations of tebipenem over 10 days of oral administration of TBPM-PI-HBr.
Time Frame: Day 1 through Day 14
|
PK concentration of tebipenem will be measured in feces.Concentrations of tebipenem will be plotted for each participant.
|
Day 1 through Day 14
|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: Incidents of treatment-emergent adverse events from Day 1 through last follow-up visit (180 days after last dose)
|
To assess the incidents of treatment-emergent adverse events following 10 days of oral TBPM-PI-HBr administration
|
Incidents of treatment-emergent adverse events from Day 1 through last follow-up visit (180 days after last dose)
|
|
Incidence of abnormal safety laboratory assessments [Safety and Tolerability]
Time Frame: Incidents of abnormal safety laboratory assessments from Day 1 through last follow-up visit (180 days after last dose)
|
To assess the incidents of abnormal hematology, biochemistry, coagulation and urinalysis assessments following 10 days of oral TBPM-PI-HBr administration
|
Incidents of abnormal safety laboratory assessments from Day 1 through last follow-up visit (180 days after last dose)
|
|
Incidence of abnormal vital sign assessments [Safety and Tolerability]
Time Frame: Incidents of abnormal vital sign assessments from Day 1 through last follow-up visit (180 days after last dose)
|
To assess the incidents of abnormal heart rate, blood pressure and body temperature assessments following 10 days of oral TBPM-PI-HBr administration
|
Incidents of abnormal vital sign assessments from Day 1 through last follow-up visit (180 days after last dose)
|
|
Incidence of abnormal physical exam assessments [Safety and Tolerability]
Time Frame: Incidents of abnormal physical exam assessments from Day 1 through last follow-up visit (180 days after last dose)
|
To assess the incidents of abnormal body system assessments following 10 days of oral TBPM-PI-HBr administration
|
Incidents of abnormal physical exam assessments from Day 1 through last follow-up visit (180 days after last dose)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation of intestinal microbiota patterns with tebipenem concentrations measured in feces.
Time Frame: Day 1 through last follow-up visit (180 days after last dose)
|
Measurement of concentrations of TBPM in feces using bioactivity techniques and correlate changes in microbiota as evidenced by various microbiological techniques (eg.
microbial diversity, colony counts, and molecular methods).
|
Day 1 through last follow-up visit (180 days after last dose)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Steffan Rosenborg, Karolinska Universitetssjukhuset
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SPR994-103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
NCT01739647CompletedHealthy Elderly Volunteers | Healthy Young Volunteers
-
NCT02922933CompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers
-
NCT02922946CompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human Volunteers
-
NCT04753580CompletedHealthy Volunteers | Frail Volunteers
-
NCT03769389CompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy Volunteers
-
NCT03194139Completed
-
NCT03164109Completed
-
NCT03163173CompletedHealthy | Healthy Volunteers
-
NCT06646458CompletedHealthy Elderly | Healthy Volunteers
-
NCT03278535CompletedHealthy Volunteers | Healthy Subjects | Healthy Adults
Clinical Trials on TBPM-PI-HBr
-
NCT04625855Completed
-
NCT04178577Completed
-
NCT04421885Completed
-
NCT03788967CompletedAcute Pyelonephritis | Complicated Urinary Tract Infection
-
NCT06727136Completed
-
NCT04368585Completed
-
NCT02853058UnknownLabor Complication